Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Pharmacology|March 31, 2004
No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240Nancy E Martin, Stanley R Howell, Louis L Martin, et al.Journal of Clinical Pharmacology|August 3, 2004
Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteersGary T Emmons, Rick Argenti, Louis L Martin, et al.The Journal of Urology|June 4, 2013
Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstructionVictor W Nitti, Steven Rosenberg, David H Mitcheson, et al.BMC Urology|September 20, 2013
Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trialVik Khullar, Javier Cambronero, Javier C Angulo, et al.Journal of Clinical Pharmacology|May 20, 2003
Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteersNancy E Martin, Kathryn R Collison, Louis L Martin, et al.Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|April 17, 2013
Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteersGary D Novack, Richard A Lewis, Roger Vogel, et al.Kidney Medicine|August 1, 2020
Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label StudiesJay B Wish, Marcelo G Rocha, Nancy E Martin, et al.Pageof 2